| Safety: demyelinating diseases ‐ multiple sclerosis ‐ acute disseminated encephalomyelitis |
|
Patient or population: children 9 months to 15 years old
Setting: general population
Intervention: MMR vaccine
Comparison: unvaccinated |
| Outcomes |
Anticipated absolute effects* (95% CI) |
Relative effect
(95% CI) |
№ of participants
(studies) |
Certainty of the evidence
(GRADE) |
| Risk of demyelinating diseases ‐ multiple sclerosis ‐ ADEM
amongst unvaccinated |
Risk of demyelinating diseases ‐ multiple sclerosis ‐ ADEM
amongst vaccinated |
| Case‐control ‐ multiple sclerosis |
Study population |
OR 1.13
(0.62 to 2.05) |
206 cases, 888 controls
(1 observational study) |
⊕⊕⊝⊝
LOW |
| 0 per 1000 |
0 per 1000
(0 to 0) |
| Case‐control ‐ ADEM |
Study population |
OR 1.03
(0.44 to 2.42) |
272 cases, 1096 controls
(1 observational study) |
⊕⊕⊝⊝
LOW |
| 0 per 1000 |
0 per 1000
(0 to 0) |
| *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
ADEM: acute disseminated encephalomyelitis; CI: confidence interval; MMR: measles, mumps, rubella vaccine; OR: odds ratio |
|
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. |
